Prime Capital Investment Advisors LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,455 shares of the medical research company's stock after selling 1,420 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $5,230,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in TMO. Signature Resources Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares in the last quarter. New Millennium Group LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $29,000. Stephens Consulting LLC raised its position in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Headlands Technologies LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $32,000. Finally, Bank & Trust Co bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $33,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific Stock Up 0.2 %
TMO traded up $1.15 during midday trading on Wednesday, reaching $541.90. 1,199,648 shares of the company were exchanged, compared to its average volume of 1,461,625. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company's fifty day moving average price is $591.27 and its 200 day moving average price is $583.32. The company has a market cap of $207.28 billion, a price-to-earnings ratio of 33.97, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $455.22 and a one year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the prior year, the business earned $5.69 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's payout ratio is 9.78%.
Analyst Ratings Changes
Several brokerages recently commented on TMO. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating on the stock in a research note on Thursday, October 24th. Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 23rd. Morgan Stanley increased their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. TD Cowen increased their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $649.33.
Read Our Latest Research Report on Thermo Fisher Scientific
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Marc N. Casper sold 9,000 shares of the firm's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at approximately $8,076,178.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,150 shares of company stock worth $20,651,865. Insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
